Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2014

View Archived Issues

Caspase-6 miRNA improves Huntington's disease manifestations in a mouse model

New irreversible pan-FGFR inhibitors with high in vivo activity against FGFR-dependent cancers

Synthetic Biologics reports topline results from phase Ia trial of SYN-004

Sevion forms antibody discovery collaboration with Janssen

MacroGenics enters collaboration agreement with Janssen to develop MGD-011

Achillion reports results from two studies of HCV regimen

NEURON BioPharma patents new neuroprotective statins

VBL Therapeutics reports phase IIa data for VB-111 in recurrent thyroid cancer

Celgene begins phase III study of apremilast in patients with active Behcet's disease

Kite Pharma submits IND application for phase I/II trial of KTE-C19

Repurposing study suggests potential of known compounds against EBV

Abbott completes acquisition of medical device company

Tekmira authorized to start phase I trial of RNAi therapeutic for HBV infection

Tiziana Life Sciences licenses anti-CD3 monoclonal antibody from NovImmune

Bio-Path to begin development of liposomal Bcl-2 in follicular lymphoma

Ferroportin shows promising data as a biomarker for multiple myeloma

BARDA provides funding to speed development of NewLink/Merck & Co. Ebola vaccine

Acturum Life Science reports development of gamma-secretase modulators

FDA approves Namzaric for Alzheimer's disease

Sorrento Therapeutics develops anti-PD-1 MAbs

Biogen Idec reports chimeric FVII-XTEN-anti-GPIIb/IIIa molecules

GSK divulges EZH2 inhibitors

FDA grants emergency use authorization for LightMix Ebola Zaire rRT-PCR Test

Safinamide NDA resubmitted to FDA

FDA issues complete response letter for Actavis' nebivolol/valsartan NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...